





Scheme S1. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of DCK.




Scheme S2. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of 2-oxo-PCE.




Scheme S3. The EI-MS and ESI-MS/MS spectra of MXE.




Scheme S4. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of MXE.




Scheme S5. The EI-MS and ESI-MS/MS spectra of ketamine.




Scheme S6. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of ketamine.




Scheme S7. The EI-MS and ESI-MS/MS spectra of F-ketamine.




Scheme S8. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of F-ketamine.




Scheme S9. The EI-MS and ESI-MS/MS spectra of Br-ketamine.




Scheme S10. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of Br-ketamine.




Scheme S11. The EI-MS and ESI-MS/MS spectra of NENK.




Scheme S12. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of NENK.




Scheme S13. The EI-MS and ESI-MS/MS spectra of DMXE.



Scheme S14. a). The EI-MS and b). ESI-MS/MS fragmentation pathways of DMXE.



Scheme S15. The ^{1}H NMR spectra of compound 1.



Scheme S16. The $^{1}H/^{1}H$ COSY spectra of compound 1.